Comparative Pharmacology
Head-to-head clinical analysis: ETHINYL ESTRADIOL LEVONORGESTREL versus FEMTRACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHINYL ESTRADIOL LEVONORGESTREL versus FEMTRACE.
ETHINYL ESTRADIOL; LEVONORGESTREL vs FEMTRACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropins (FSH and LH) from the anterior pituitary, inhibiting ovulation. Also increases cervical mucus viscosity and induces endometrial changes that reduce implantation likelihood.
Estrogen receptor agonist; binds to estrogen receptors, modulating gene transcription and cellular proliferation in target tissues.
1 tablet (0.03 mg ethinyl estradiol / 0.15 mg levonorgestrel) orally once daily for 21 consecutive days, followed by 7 days of placebo
1 to 2 mg orally once daily; for testosterone replacement in adult males, 2 to 4 mg orally once daily.
None Documented
None Documented
Ethinyl estradiol: ~13-27 hours (terminal); Levonorgestrel: ~16-33 hours (terminal). Clinically, steady-state is reached within 5-7 days; elimination half-life supports once-daily dosing with potential accumulation.
Terminal elimination half-life is approximately 12-14 hours, supporting once-daily dosing in clinical use.
Renal: Ethinyl estradiol ~40% as glucuronide and sulfate conjugates; levonorgestrel ~20% as metabolites. Fecal: Ethinyl estradiol ~60%; levonorgestrel ~80% via biliary excretion.
Primarily renal; ~40% as unchanged drug and glucuronide conjugates. Biliary/fecal elimination is minor (~10-15%).
Category D/X
Category C
Estrogen
Estrogen